Allergists and clinical immunologists around the world are increasingly faced with the task of
addressing drug allergy and hypersensitivity due to the increase in drug reactions …

Abstract The World Allergy Organization (WAO) Guidelines for the assessment and
management of anaphylaxis are a widely disseminated and used resource for information …

Drug hypersensitivity reactions (DHR s) are a matter of great concern, both for outpatient
and in hospital care. The evaluation of these patients is complex, because in vivo tests have …

Background The increasing use of mAbs has led to a rise in hypersensitivity reactions
(HSRs), which prevent their use as first-line therapy. HSRs' symptoms, diagnostic tools, and …

Drug hypersensitivity reactions (DHRs) to intravenous drugs can be severe and might leave
patients and doctors in a difficult position where an essential treatment or intervention has to …

Opinion statement Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune
disease of the central nervous system that primarily attacks the optic nerves and spinal cord …

Fifteen monoclonal antibodies (mAbs) are currently registered and approved for the
treatment of a range of different cancers. These mAbs are specific for a limited number of …

Hypersensitivity reactions (HSRs) to monoclonal antibodies (mAbs) are increasingly
frequent as this class of therapeutic agents is rapidly expanding. Immediate and …

Biologicals are crucial targeted therapeutic agents in oncological, immunological, and
inflammatory diseases, and their use in clinical practice is broadening. In recent years, the …

Biologic agents have substantially advanced the treatment of immunological disorders,
including chronic inflammatory and autoimmune diseases. However, these drugs are often …